Oxime cure and alkoxy cure describe the byproduct chemistry released as a one-part RTV silicone sealant hardens on exposure to atmospheric moisture. Patent claims in this dataset distinguish the two because they affect substrate adhesion, odour, corrosion of adjacent metals, and cure speed, so a formulation claim usually specifies which cure chemistry and which catalyst system it depends on. The representative filing in this dataset, US5519104A, is built specifically around alkoxy cure with a dual dibutyltin catalyst system aimed at extending tooling time without hurting cured properties. Reviewing which cure chemistry a competitor has claimed is usually the fastest way to see whether a new formulation sits inside or outside their protection.

This dataset ranks 73 companies by patent family count, with the leading assignee holding 79 of the 289 records in scope and a steep drop to 16 records at fifth place and 10 at tenth. The top 5 assignees combined account for 50.9% of all records, and the top 10 combined account for 72.3%, so ownership is concentrated among a small group of large silicone and adhesives formulators rather than spread evenly. Recent-year momentum for the top-ranked assignees shows 0 filings in the latest tracked year across several of them, which is consistent with publication lag rather than a genuine pullback. Anyone assessing competitive position should treat the ranked list as the current owners of claim space, not a static picture.

Filing activity peaked at 33 records in 2019, fell through the early 2020s, and then rose again from 2 records in 2021 to 8 in 2024 — a +300% increase over that three-year span. Because publication typically lags actual filing by around 18 months, the 2025 and 2026 figures in this dataset are still incomplete and should not be read as evidence of a slowdown. The 2021–2024 rebound is the most reliable recent signal available and suggests renewed interest in the space rather than a mature, declining field. Watching who files in the next reporting window will clarify whether this rebound continues.

C08L, covering polymer compositions, appears in 42.9% of the 289 records and is the single largest class, followed by C08G condensation polymers at 23.2% and C08K polymer additives at 22.5%. Adhesives (C09J) and coatings (C09D) each cover close to a fifth of records, reflecting how RTV sealant chemistry overlaps with adjacent bonding and coating applications. Less expected is the medical-device presence: A61L sterilising and disinfecting claims cover 10.0% of records and A61F implant and prosthesis claims cover 9.0%, both large enough to matter for anyone drafting claims that might touch medical hardware. Because records can carry multiple IPC codes, these shares are not mutually exclusive and add up to more than 100% of the record total.

US5519104A, assigned to General Electric Company and granted in 1996, claims a specific dual-catalyst approach to one-component alkoxy cure RTV silicone sealants — using either a particular organotin compound or an approximately equimolar mixture of dibutyltin diacetate and dibutyltin dilaurate — to extend tooling time without harming cured performance. It does not block alkoxy cure chemistry generally, nor oxime cure systems; its scope is tied to that specific catalyst combination and the tooling-time benefit it produces. A new entrant working with a different catalyst system, a different cure mechanism, or targeting a different performance property, such as weathering resistance or joint-movement tolerance rather than tooling time, would likely sit outside its claims. Any freedom-to-operate check should focus narrowly on catalyst chemistry rather than treating this filing as covering alkoxy-cured RTV sealants broadly.